National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road, New Delhi PREFACE

Size: px
Start display at page:

Download "National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road, New Delhi 110001 PREFACE"

Transcription

1

2

3

4

5 National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road, New Delhi Injeti Srinivas, IAS Chairman 27 February 2015 PREFACE The National Pharmaceutical Pricing Authority (NPPA) is mandated with the task of implementing the Drugs (Prices Control) Order (DPCO) 2013, which aims at making available all essential and lifesaving medicines to all at affordable prices through the instrumentality of price control. Drug price control is not something peculiar to India, but one that is prevalent in most countries, including many developed countries, though the methodology of price control may differ from one country to another. 2. Unlike the DPCO 1995, which adopted a cost-based approach for price fixation in respect of scheduled drugs, the DPCO 2013 adopts a market-based approach for price fixation. Second, the National List of Essential Medicines (NLEM) 2011 is adopted as the primary basis for determining essentiality, and is accordingly incorporated in the First Schedule to the DPCO 2013, which constitutes the list of scheduled medicines for the purpose of price control. Third, the price control is applied to specific formulations with reference to the medicine (active pharmaceutical ingredient), route of administration/ dosage form and strength as contained in the First Schedule. 3. Under the market-based approach, the ceiling price of a scheduled drug is determined by first working out the simple average of price to retailer (PTR) in respect of all brandedgeneric and generic versions of that particular drug formulation having a market share of 1 percent and above, and then adding a notional retailer margin of 16 percent to it. The maximum retail price (MRP) for that particular drug formulation must not exceed the notified ceiling price plus applicable local taxes.

6 National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road, New Delhi All the existing manufacturers (including importers and marketers) of a scheduled formulation, selling branded or generic or both versions of that formulation at a price higher than the ceiling price plus local applicable taxes are required to reduce it to at least that level. At the same time, all existing manufacturers (including importers and marketers) of that formulation who are selling it below that price are required to maintain their existing MRP. Implementation of the price notification is to be communicated, in Form-V of Schedule II to the DPCO 2013, to all dealers, State Drug Controllers and NPPA immediately. Also the current price list of scheduled drugs has to be displayed by every dealer and retailer. 5. The ceiling price fixed for each scheduled formulation becomes operative and legally enforceable from the date on which the price is notified in the Gazette of India Extraordinary. In other words, the medicine cannot be sold at an MRP exceeding the ceiling price plus applicable local taxes from the date of price notification. However, for stock manufactured or available in the market prior to publication of the ceiling price, a grace period of 45 days is available to facilitate recall and/ or reprinting of the revised MRP on the label of the medicine in accordance with the notified ceiling price. But under no circumstances does it allow sale of a medicine at the pre-revised price even during the 45-day grace period, as the same stock keeping unit (SKU) of a particular medicine should not be offered to the consumer at a price exceeding the price specified in the current price list or the price indicated on the label of the medicine pack, whichever is less. Similarly, all batches manufactured after the price notification must necessarily conform to the notified ceiling price. 6. The notified ceiling price with respect to each scheduled formulation is valid for a period of five years from the date of original price notification, but subject to annual revision to be notified by NPPA which would be effective from the first day of April every year as per the annual wholesale price index (WPI) notified by the Department of Industrial Policy & Promotion with respect to the previous calendar year. The revision may mean increase or decrease in ceiling price depending upon whether the WPI is positive or negative. The manufacturers (including importers and marketers) are free to avail themselves of the annual revision in case of increase, without obtaining prior approval of the Government, but they are required to exercise their decision in this regard within 15 days of such revision and report to the NPPA in Form-II of Schedule II to DPCO 2013 failing which it shall be construed that the company has opted for non-revision of MRP and the concerned manufacturer shall

7 National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road, New Delhi be liable to deposit the amount charged over and above the pre-revised MRP, along with interest from the date of overcharging. Further, they shall be bound to decrease their MRP correspondingly in case of decrease in the ceiling price due to negative WPI. 7. Non-compliance with the notified ceiling price or, in other words, the MRP breaching ceiling price plus applicable local taxes would be tantamount to overcharging the consumer, which is liable to be recovered along with interest thereon from the date of overcharging. The excess collection on account of overcharging along with interest is recoverable as arrears to land revenue under the Public Demand Recovery Act. 8. Further, non-compliance of price notification issued by NPPA, depending upon the gravity of the offence, could also attract prosecution under the Essential Commodities Act (ECA), Section 7 of the ECA 1955 provides for imprisonment for a term which shall not be less than 3 months, but which may extend to seven years and shall also be liable for fine. Section 9 of the ECA, 1955 makes false statements/ information also punishable with imprisonment for a term which may extend to five years or with fine or with both. Under section 10 of the ECA, 1955, offences committed by companies are punishable, and shall apply to every person who, at the time the contravention was committed, was in charge of, and was responsible to, the company for conduct of the business of the company as well as the company, shall be deemed to be guilty of the contravention and shall be liable to be proceeded against and punished accordingly. Every offence committed under the Essential Commodities Act, 1955 is a cognizable offence. 9. Implementation of the DPCO 2013 is the joint responsibility both NPPA and State Drug Controllers. Accordingly, most State Governments/ Union Territories have duly empowered the State Drug Controller and Drug Inspectors under paragraph 30 (1) of DPCO 2013, which allows any Gazetted Officer of the Central Government or of a State Government, as the case may be, to exercise the power of entry, search and seizure to ensure that the provisions of the DPCO have been complied with. The States which are yet to do this are requested to do so at the earliest. Further, as part of the regular enforcement activity of the Office of the State Drug Controller, on similar lines as done with respect to drug sample testing under the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945, every Drug Inspector should be given a monthly target for purchasing scheduled formulations, preferably 5 to 10 samples a month, to verify price compliance, and report

8 National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road, New Delhi price violations for taking necessary action against erring manufacturers, importers, marketers, and dealers (including retailers). The State Drug Controller may compile the monthly reports of individual Drug Inspectors, and submit a monthly consolidated report to NPPA in the following format:-. Sl.No. Name and address of Manufacturer and Marketer in case of separate entities Brand Name, if any Pack Size Batch No. and manufacturing date Maximum Retail Price (MRP) Ceiling Price/ unit Gazette Notification No. and date Remarks (9) The report should be accompanied with supporting documents such as photocopy of sample pack with MRP, Batch No. and Manufacturing date, Name of Manufacturer and Marketer (if applicable). While collecting samples from the market, preference may be given to those formulations that are of mass consumption; each sample may be procured from 2 to 3 locations in order to get a geographical spread. Finally, the samples collected should correspond to important therapeutic groups in relation to disease burden in the State. This activity should be taken up with utmost sincerity in order to prevent consumer exploitation and protect public interest 10. At present the DPCO 2013 contains 680 scheduled drug formulations spread across 27 therapeutic groups, which effectively comes to 628 scheduled drug formulations if we net those appearing in more than one therapeutic group. As on date, the NPPA has fixed and notified the ceiling prices with respect to 509 scheduled formulations, apart from notification of annual WPI-linked revision whenever due. With regard to the remaining 119 scheduled drug formulations, 17, which are common to both DPCO 1995 and DPCO 2013, are not yet due for revision. With respect to the residual 102 scheduled drug formulations, the NPPA has not been able to fix the ceiling prices due to non-availability of corresponding market-based PTR data, efforts for which are continuously on, and those ceiling prices shall be notified as soon as the said data is available. 11. The Compendium of Notified Ceiling Prices of Scheduled Drugs 2015 has been brought out with the objective of disseminating information related to notified ceiling prices in respect of scheduled drugs, to all stakeholders, particularly consumers and consumer welfare

9 National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road, New Delhi organisations/ NGOs; manufacturers, including importers and marketers of pharmaceuticals products; stockist/ distributors, dealers and retailers; doctors and public health experts; and most importantly enforcement functionaries (NPPA, State Drug Controller and Drug Inspectors) for carrying out monitoring and enforcement activities. Apart from serving as a compendium of notified ceiling prices, it is also expected to help in propagating the NLEM, which is basically aimed at promoting scientific and rational use of medicines that is both clinically-effective and cost-effective. 12. I sincerely hope that all stakeholders will find this compendium extremely useful as a ready reckoner. The enforcement functionaries may find this compendium useful in carrying out monitoring and enforcement activities with regard to price compliance under DPCO The NPPA has provided on its website an online facility to lodge complaints related to price and availability of pharmaceuticals, which may be used by consumers, NGOs and enforcement functionaries to report cases of overcharging or non-availability of medicines, if any. A soft copy of the compendium is also placed on the NPPA website along with copies of related Gazette of India Extraordinary price notifications in PDF format. Although every effort has been made to maintain accuracy in the compendium, the NPPA shall not be responsible for any error or mistake that may have inadvertently crept into the compendium. The reader is, therefore, advised to refer to the relevant official Gazette notification before taking any action on the basis of this compendium. (Injeti Srinivas)

10 DISCLAIMER The information contained herein is not a substitute to ceiling prices notified in the Gazette of India Extraordinary. For the official version, please refer to the relevant Gazette Notification issued in this regard, which may be accessed from the NPPA website at

11

12 SCHEDULE-I [Refer Paragraph 2(t), 2(zb)] of DPCO, 2013 NATIONAL LIST OF ESSENTIAL MEDICINES 2011 SECTION : 1 - ANESTHESIA 1.1 General Anesthetics and Oxygen Sl. No. Medicines Route of Strengths Unit Ceiling Price S.O. Date of (i) Ether Inhalation (ii) Halothane with vaporizer Inhalation 1ml (E) ml (E) ml (E) (iii) Isoflurane Inhalation 1ml E) ml (E) ml (E) (iv) Ketamine Hydrochloride Injection 10mg/ml 1ml (E) ml (E) (v) Injection 50mg/ml 1ml (E) ml (E) ml (E) (vi) Nitrous Oxide Inhalation Cubic Meter (E) Cubic Meter (E) Cubic Meter (E) (vii) Oxygen Inhalation Cubic Meter (E) Cubic Meter (E) Cubic Meter (E) (viii) Thiopentone Sodium Injection 0.5 gm powder Each Pack (E) Each Pack (E) Each Pack (E) Injection 1 gm powder 1 gm (E) gm (E) gm (E) Added Medicines (x) Sevoflurane Inhalation 1 ml (E) ml (E) ml (E)

13 (xi) Propofol Injection 1% oil Each Pack (E) suspension 1ml 2535(E) ml (E) ml (E) ml (E) Local Anesthetics (i) Bupivacaine Hydrochloride Injection 0.25% 1 ml (E) ml (E) ml (E) (ii) Bupivacaine Hydrochloride Injection 0.5% 1 ml (E) ml (E) ml (E) (iii) Bupivacaine Hydrochloride Injection 0.5% to be mixed 1 ml (E) with 7.5% 1 ml (E) glucose solution 1 ml (E) (iv) Lignocaine Hydrochloride Topical Forms 2-5% 1 ml / gm (E) ml / gm (E) ml / gm (E) Injection 1-2% Spinal 5%+7.5% Glucose 1% Each Pack (E) Each Pack (E) Each Pack (E) % 1 ml (E) ml (E) ml (E) (v) Lignocaine Hydrochloride Injection 1%+ Each Pack (E) Adrenaline 1:200,000 Each Pack (E) Each Pack (E) (vi) Lignocaine Hydrochloride Injection 2%+ 1 ml (E) Adrenaline 1:200,000 1 ml (E) ml (E) ml (E)

14 Added Medicines (vii) EMLA cream Cream 1 gm (E) gm (E) gm (E) Preoperative Medication and Sedation for Short Term Procedures (i) Atropine Sulphate Injection 0.6 mg/ml 1 ml (E) ml (E) ml (E) (ii) Diazepam Tablets 5 mg 1 Tablet (E) Tablet (E) Tablet (E) Diazepam Injection 5 mg / ml 1 ml (E) ml (E) ml (E) Diazepam Syrup 2mg/5ml Diazepam Suppository 5 mg 1 Suppository (E) Suppository (E) (iii) Midazolam Injection 1 mg / ml 1ml (E) ml (E) ml (E) mg / ml 1ml (E) ml (E) ml (E) (iv) Morphine Sulphate Injection 10 mg / ml 1ml (E) ml (E) ml (E) (v) Promethazine Syrup 5 mg / 5 ml 1 ml (E) Syrup/Elixir 3574(E) ml (E) ml (E)

15 Section: 2 - Analgesics, Antipyretics, Nonsteroidal Anti-inflammatory Medicines, Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders 2.1: Non-Opioid Analgesics, Antipyretics and Nonsteroidal Anti-inflammatory Medicines (i) Acetyl Salicylic Acid Tablets 325mg 1 Tablet (E) Tablet (E) Acetyl Salicylic Acid Tablets 350 mg (ii) Diclofenac Tablets 50 mg 1 Tablet (E) Tablet (E) Tablet (E) (iii) Ibuprofen Tablets 200 mg Injection 25 mg / ml 1 ml (E) ml (E) ml (E) ml (E) Tablets 400 mg Syrup 100mg/5ml 1 ml (E) ml (E) ml (E) (iv) Paracetamol Injection 150 mg / ml 1ml (E) ml (E) ml (E) ml (E) Syrup 125 mg / 5ml 1 ml (E) ml (E) ml (E) ml (E) Tablets 500 mg 1 Tablet (E) Tablet (E) Tablet (E) Suppository 80 mg 1 Suppository (E) Suppository (E) Suppository (E) Suppository (E)

16 Suppository 170 mg 1 Suppository (E) Suppository (E) Suppository (E) Suppository (E) Opioid Analgesics (i) Morphine Sulphate Injection 10 mg / ml 1ml (E) ml (E) ml (E) Tablets 10 mg 1 Tablet (E) Tablet (E) Tablet (E) (ii) Tramadol Injection 50 mg/ml 1 ml (E) ml (E) ml (E) Capsule 50 mg 1 Capsule (E) Capsule (E) Capsule (E) Capsule (E) Capsule 100 mg (iii) Fentanyl Injection 50µg/ml (2ml 1 ml (E) ampoule) 1 ml (E) ml (E) Medicines used to treat Gout (i) Allopurinol Tablets 100 mg 1 Tablet (E) Tablet (E) Tablet (E) (ii) Colchicine Tablets 0.5 mg 1 Tablet (E) Tablet (E) Tablet (E) Disease modifying agents used in Rheumatoid disorders (i) Azathioprine Tablets 50 mg 1 Tablet (E) Tablet (E) Tablet (E) (ii) Methotrexate Tablets 5mg 1 Tablet (E) Tablet (E) Tablet (E)

17 Tablets 7.5mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 10mg 1 Tablet (E) Tablet (E) Tablet (E) (iii) Sulfasalazine Tablets 500 mg 1 Tablet (E) Tablet (E) Tablet (E) Added medicines (iv) Hydroxychloroquine Tablets 200 mg 1 Tablet (E) Phosphate 1 Tablet (E) Tablet (E) (v) Leflunomide Tablets 10mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 20 mg 1 Tablet (E) Tablet (E) Tablet (E) Section: 3 - Antiallergics and Medicines used in Anaphylaxis (i) Adrenaline Bitartrate Injection 1 mg / ml 1 ml (E) ml (E) ml (E) (ii) Chlorpheniramine Maleate Tablets 4 mg 1 Tablet (E) Tablet (E) Tablet (E) (iii) Dexchlorpheniramine Syrup 0.5mg /5ml 1 ml (E) Maleate 1 ml (E) ml (E) (iv) Dexamethasone Tablets 0.5 mg 1 Tablet (E) Tablet (E) Tablet (E) Injection 4 mg / ml 1 ml (E) ml (E) ml (E)

18 (v) Hydrocortisone Sodium Injection 100 mg Each Pack (E) Succinate Each Pack (E) Each Pack (E) (vi) Pheniramine Maleate Injection mg / ml 1 ml (E) ml (E) (vii) Prednisolone Tablets 5 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 10 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 20 mg 1 Tablet (E) Tablet (E) Tablet (E) (viii) Promethazine Tablets 10 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 25 mg 1 Tablet (E) Tablet (E) Tablet (E) Added Medicines (ix) Cetrizine Tablets 10mg 1 Tablet (E) Tablet (E) Tablet (E) Syrup 5 mg/ml 1 ml (E) ml (E) ml (E) Section: 4 - Antidotes and Other Substances used in Poisonings (i) Activated Charcoal Oral : Nonspecific - 7 -

19 4.2: Specific (i) Atropine Sulphate Injection 1 mg/ml (ii) Specific Antisnake venom Injection -- Polyvalent Solution/ Lyophilyzed Polyvalent Serum (iii) Calcium Gluconate Injection 100mg/ml 10ml Ampoule (E) ml Ampoule (E) ml Ampoule (E) (iv) Desferrioxamine Mesylate Injection 500mg Each Pack (E) Each Pack (E) Each Pack (E) (v) Methylthioninium Chloride Injection 10 mg / ml (Methylene Blue) (vi) Penicillamine Tablets or 250 mg 1 Capsule (E) Capsules 1 Capsule (E) Capsule (E) (vii) Dimercaprol Injection in oil 50 mg / ml (viii) Flumazenil Injection 0.1 mg / ml (ix) Sodium Nitrite Injection 30 mg / ml 1 ml (E) ml (E) (x) Sodium Thiosulphate Injection 250 mg/ ml (xi) Naloxone Injection 0.4mg/ml 1 ml (E) ml (E) ml (E) (xii) Pralidoxime Chloride Injection 25 mg/ml (2-PAM) Added medicines: (xiii) N-acetylcysteine Injection 200 mg/ml(5 ml) 1 ml (E) ml (E) ml (E)

20 Section: 5 - Anticonvulsants/ Antiepileptics (i) Carbamazepine Tablets 100mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 200mg 1 Tablet (E) Tablet (E) Tablet (E) Syrup 100 mg/5ml 1 ml (E) ml (E) (ii) Diazepam Injection 5 mg/ml 1 ml (E) ml (E) ml (E) (iii) Magnesium sulphate Injection 500 mg /ml 1 ml (E) ml (E) ml (E) (iv) Phenobarbitone Tablets 30 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablet (E) Tablets 60 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablet (E) Injection 200 mg/ml 1 ml (E) ml (E) ml (E) Syrup 20 mg/5ml 1 ml (E) ml (E) ml (E) (v) Phenytoin Sodium Capsules or 50 mg 1 Tablet (E) Tablets 1 Tablet (E) Tablet (E) mg 1 Tablet (E) Tablet (E) Tablet (E) Capsule (E) Capsule (E) Capsule (E)

21 Syrup 25mg/ml 100mg 1ml (E) ml (E) ml (E) Injection 50 mg/ml 1 ml (E) ml (E) ml (E) mg/ml 1ml (E) ml (E) (vi) Sodium Valproate Tablets 200 mg 1 Tablet (E) Tablet E) Tablet (E) Tablets 500mg 1 Tablet (E) Tablet (E) Tablet (E) Syrup 200 mg/5ml 1 ml (E) ml (E) ml (E) Injection 100 mg/ml 1 ml (E) ml (E) ml (E) Added Medicines (vii) Lorazepam Injection 2mg/ml 1ml (E) ml (E) ml (E) Section: 6 - Anti-infective Medicines 6.1 Anthelminthics Intestinal Anthelminthics (i) Albendazole Tablets 400 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablet (E)

22 Suspension 200 mg/ 5 ml 1 ml (E) ml (E) ml (E) Added Medicines (ii) Piperazine Tablets 4.5 gm Solution 750mg/5ml 1 ml (E) ml (E) ml (E) Antifilarials (i) Diethylcarbamazine citrate Tablets 50 mg 1 Tablet (E) Tablet (E) Tablet (E) Antischistosomals and Antitrematode Medicines (i) Praziquantel Tablets 600 mg 1 Tablet (E) Tablet (E) Tablet (E) Antibacterials Beta lactam medicines (i) Amoxicillin Powder for 125 mg / 5 ml 1 ml (E) suspension 1 ml (E) ml (E) Capsules 250 mg 1 Capsule (E) Capsule (E) Capsule (E) Capsules 500 mg 1 Capsule (E) Capsule (E) Capsule (E) (ii) Ampicillin Capsules 250 mg 1 Capsule (E) Capsule (E) Capsule (E) Capsules 500 mg 1 Capsule (E) Capsule (E) Capsule (E)

23 Powder for 125 mg / 5 ml 1 ml (E) suspension 1 ml (E) ml (E) Injection 500 mg Each Pack (E) Each Pack (E) Each Pack (E) (iii) Benzathine Benzylpenicillin Injection 6 lacs units 1 Injection (E) ml (E) ml (E) Injection 12 lacs units 1 Injection (E) ml (E) ml (E) (iv) Cefotaxime Injection 125 mg Each Pack (E) Each Pack (E) Injection 250 mg Each Pack (E) Each Pack (E) Injection 500 mg Each Pack (E) Each Pack (E) (v) Ceftazidime Injection 250mg Each Pack (E) Each Pack (E) Each Pack (E) Injection 1gm Each Pack (E) Each Pack (E) Each Pack (E) (vi) Ceftriaxone Injection 250mg Each Pack (E) Each Pack (E) Each Pack (E) Injection 1gm Each Pack (E) Each Pack (E) Each Pack (E) (vii) Cephalexin Syrup 125 mg / 5 ml 1 ml (E) ml (E) ml (E) Capsules 250 mg 1 Capsule (E) Capsule (E) Capsule (E)

24 Capsules 500 mg 1 Capsule (E) Capsule (E) Capsule (E) (viii) Cloxacillin Capsules 250 mg 1 Capsule (E) Capsule (E) Capsules 500 mg 1 Capsule (E) Capsule (E) Injection 250 mg Each Pack (E) Each Pack (E) Liquid 125mg/ 5 ml Added Medicines (ix) Amoxicillin+Clavulinic acid Tablets 625 mg 1 Tablet (E) Tablet (E) Tablet (E) Powder for 228.5mg/5ml 1 ml (E) suspension 1 gm (E) suspension 1 gm (E) Injection 600mg Each pack (E) Each pack (E) Each pack (E) Injection 1.2gm Each pack (E) Each pack (E) Each pack (E) (x) Cefixime Tablet 100 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablet 200mg 1 Tablet (E) Tablet (E) Tablet (E) Other antibacterials (i) Amikacin Injection 250 mg / 2 ml 1 ml (E) ml (E) ml (E)

25 (ii) Azithromycin Tablets 100mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 250mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 500mg 1 Tablet (E) Tablet (E) Tablet (E) Tablet (E) Suspension 100mg/5ml 1 ml (E) ml (E) ml (E) Injection 500mg Each Pack (E) Each Pack ` 1156(E) Each Pack (E) (iii) Ciprofloxacin Hydrochloride Injection 200 mg /100 ml 1 ml (E) ml (E) S.O. No. 1784(E) dt withdraw with immediate effect 1823(E) ml (E) ml (E) Tablets 250 mg 1 Tablet (E) Tablet (E) Tablets 500 mg 1 Tablet (E) Tablet (E) (iv) Co-Trimoxazole Tablets mg 1 Tablet (E) (Trimethoprim + 1 Tablet (E) Sulphamethoxazole) Tablets mg 1 Tablet (E) Tablet (E) Tablet (E) Tablet (E) Suspension mg/5 ml 1 ml (E) ml (E) ml (E) (v) Doxycycline Tablets 100 mg 1 Tablet (E) Tablet (E) Tablet (E)

26 (vi) Erythromycin Estolate Syrup 125 mg / 5 ml Tablets Tablets 250 mg 500 mg (v) Gentamicin Injection 10 mg/ml 1ml (E) ml (E) (vi) Metronidazole Tablet 200mg Injection 40 mg/ml 1 ml (E) ml (E) ml (E) Tablet Injection 400mg 500mg/100ml Syrup 100mg/5ml 1 ml (E) ml (E) ml (E) (vii) Nitrofurantoin Tablets 100 mg 1 Tablet (E) Tablet (E) Tablet (E) (viii) Sulphadiazine Tablets 500 mg 1 Tablet (E) Tablet (E) (ix) Vancomycin Hydrochloride Injection 500 mg Each Pack (E) Each Pack (E) Each Pack (E) Injection 1 gm Each Pack (E) Each Pack (E) Each Pack (E) Antileprosy medicines (i) Clofazimine Capsules 50 mg 1 Capsule (E) Capsule (E) Capsule (E) Capsules 100 mg 1 Capsule (E) Capsule (E) Capsule (E)

27 (ii) Dapsone Tablets 50 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 100mg 1 Tablet (E) Tablet (E) Tablet (E) (iii) Rifampicin Capsules or 150 mg 1 Tablet (E) Tablets 1 Tablet (E) Capsules or 300 mg 1 Tablet (E) Tablets 1 Tablet (E) Antituberculosis medicines (i) Ethambutol Tablets 200 mg 1 Tablet (E) Tablet (E) Tablet (E) (ii) Isoniazid Tablets 50 mg Tablets 400 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 600 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 800 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 100 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 300 mg 1 Tablet (E) Tablet (E) Tablet (E) Syrup 100 mg/5ml 1 ml (E) ml (E) ml (E) (iii) Ofloxacin Tablets 100 mg 1 Tablet (E) Tablet (E) Tablet (E)

28 Tablets 200 mg 1 Tablet (E) Tablet (E) Tablet (E) Syrup 50 mg / 5 ml 1 ml (E) ml (E) ml (E) (iv) Pyrazinamide Tablets 500 mg 1 Tablet (E) Tablet (E) Tablet (E) (v) Rifampicin Capsules/Tablets 50 mg Tablets 750 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 1000 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 1500 mg 1 Tablet (E) Tablet (E) Tablet (E) Capsules/Tablets 150 mg 1 Tablet (E) Tablet (E) Capsules/Tablets 300 mg 1 Tablet (E) Tablet (E) Capsules/Tablets 450 mg 1 Tablet (E) Tablet (E) Syrup 100 mg / 5 ml (vi) Streptomycin Sulphate Injection 0.75 gm Each Pack (E) ml (E) ml (E) gm 1 Injection (E) ml (E) ml (E)

29 6.3 Antifungal medicines (i) Amphotericin B Injection 50 mg Each Pack (E) Each Pack (E) Each Pack (E) (ii) Clotrimazole Pessaries 100 mg 1 Pessaries (E) Pessaries (E) Pessaries (E) Pessaries (E) Pessaries 200 mg 1 Pessaries (E) Pessaries (E) Pessaries (E) Pessaries (E) Gel 2% 1 gm (E) gm (E) gm (E) (iii) Fluconazole Capsules or 50 mg 1 Capsule (E) Tablets 1 Capsule (E) Tablets 1 Capsule (E) Tablet (E) Tablet (E) Tablet (E) Capsules or 100 mg 1 Capsule (E) Tablets 1 Capsule (E) Capsule (E) Tablet (E) Tablet (E) Tablet (E) Capsules or 150 mg 1 Capsule (E) Tablets 1 Capsule (E) Capsule (E) Tablet (E) Tablet (E) Tablet (E) Capsules or 200 mg 1 Capsule (E) Tablets 1 Capsule (E) Capsule (E)

30 1 Tablet (E) Tablet (E) Tablet (E) (iv) Griseofulvin Capsules or 125 mg 1 Tablet (E) Tablets 1 Tablet (E) (v) Nystatin Tablets 500,000 IU Capsules or 250 mg 1 Tablet (E) Tablets 1 Tablet (E) Pessaries 100,000 IU 6.4 Antiviral medicines Antiherpes medicines (i) Acyclovir Tablets 200 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 400 mg 1 Tablet (E) Tablet (E) Tablet (E) Injection 250 mg Each Pack (E) Each Pack (E) Each Pack (E) Injection 500 mg Each Pack (E) Each Pack (E) Each Pack (E) Suspension 400 mg / 5 ml 1 ml (E) ml (E) ml (E) Antiretroviral medicines Nucleoside reverse transcriptase inhibitors (i) Didanosine Tablets 250 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 400 mg 1 Tablet (E) Tablet (E)

31 (ii) Lamivudine Tablets 150 mg 1 Tablet (E) Tablet (E) Tablet (E) (iii) Lamivudine + Nevirapine Tablets 150 mg+200 mg 1 Tablet (E) Stavudine + 30 mg 1 Tablet (E) Tablet (E) (iv) Lamivudine + Zidovudine Tablets 150 mg+300 mg 1 Tablet (E) Tablet (E) Tablet (E) (v) Stavudine Capsules 15 mg (vi) Zidovudine Tablets 100 mg Capsules 30 mg 1 Capsule (E) Capsule (E) Capsule (E) Capsules 40 mg 1 Capsule (E) Capsule (E) Capsule (E) Tablets 300 mg 1 Tablet (E) Tablet (E) Tablet (E) ADDED MEDICINES (vii) Stavudine+Lamivudine Tablets 30mg+150mg 1 Tablet (E) Tablet (E) Tablet (E) (viii) Zidovudine+Lamivudine+ Tablets 300mg+150mg+ 1 Tablet (E) Nevirapine 200mg 1 Tablet (E) Tablet (E) Non-nucleoside reverse transcriptase inhibitors (i) Efavirenz Capsules 200 mg 1 Capsule (E) Capsule (E) Capsule (E) Capsules 600 mg 1 Capsule (E) Capsule (E)

32 (ii) Nevirapine Capsules 200 mg Suspension 50 mg / 5 ml 1 ml (E) ml (E) ml (E) Protease inhibitors (i) Indinavir Capsules 200 mg (ii) Nelfinavir Capsules 250 mg Capsules 400 mg 1 Capsule (E) Capsule (E) Capsule (E) (iii) Ritonavir Capsules 100 mg 1 Capsule (E) Capsule (E) Capsule (E) Syrup 400 mg / 5ml (iv) Saquinavir Capsules 200 mg 6.5 Antiprotozoal Medicines Antiamoebic and Antigiardiasis medicines (i) Diloxanide Furoate Tablets 500 mg 1 Tablet (E) Tablet (E) Tablet (E) (ii) Metronidazole Tablets 200 mg Tablets Injection 400 mg 500 mg /100 ml Antileishmaniasis medicines (i) Amphotericin B Injection 50 mg Each Pack (E) Each Pack (E) Each Pack (E) (ii) Pentamidine Isothionate Injection 200 mg

33 (iii) Sodium Stibogluconate Injection 100 mg / ml 1 ml (E) ml (E) ml (E) Antimalarial Medicines For curative treatment (i) Artesunate (To be used Tablets 50 mg 1 Tablet (E) only in combination with 1 Tablet (E) Sulfadoxine + 1 Tablet (E) Pyrimethamine) (ii) Chloroquine phosphate Tablets 150 mg base Injection Syrup 40 mg / ml 50 mg / 5 ml (iii) Primaquine Tablets 2.5 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 7.5 mg 1 Tablet (E) Tablet (E) Tablet (E) (iv) Pyrimethamine Tablets 25 mg 1 Tablet (E) Tablet (E) (v) Quinine sulphate Tablets 300 mg 1 Tablet (E) Tablet (E) Tablet (E) Injection 300 mg / ml 1ml (E) ml (E) ml (E) (vi) Sulfadoxine + Tablets 500 mg+ 1 Tablet (E) Pyrimethamine 25 mg 1 Tablet (E) Tablet (E) Medicines added (vii) Clindamycin Tablet 150mg

34 Tablet 300mg 1 Tablet (E) Tablet (E) Tablet (E) For prophylaxis Medicines added (i) Mefloquine Tablet 250 mg base 1 Tablet (E) Tablet (E) Tablet (E) Antipneumocystosis and Antitoxoplasmosis medicines (i) Co-Trimoxazole Tablets mg 1 Tablet (E) (Trimethoprim + 1 Tablet (E) Sulphamethoxazole) Tablets mg 1 Tablet (E) Tablet (E) Tablet (E) Tablet (E) Suspension mg/5 ml 1 ml (E) ml (E) ml (E) (ii) Pentamidine Isothionate Injection 200 mg Section: 7 -Antimigraine medicines 7.1: For treatment of acute attack (i) Acetyl Salicylic Acid Tablets mg 325mg 1 Tablet (E) Tablet (E) (ii) Dihydroergotamine Tablets 1 mg 1 Tablet (E) Tablet (E) Tablet (E)

35 (iii) Paracetamol Tablets 500 mg 1 Tablet (E) Tablet (E) Tablet (E) : For Prophylaxis (i) Propranolol Hydrochloride Tablets 10 mg 1 Tablet (E) Tablet (E) Tablet (E) mg 1Tablet (E) Tablet (E) Tablet (E) Section: 8 - Antineoplastic, immunosuppressives and medicines used in palliative care 8.1: Immunosuppressive medicines (i) Azathioprine Tablets 50 mg 1 Tablet (E) Tablet (E) Tablet (E) (ii) Cyclosporine Capsules 10 mg Capsules 25 mg 1 Capsule (E) Capsule (E) Capsule (E) Capsules 50 mg 1 Capsule (E) Capsule (E) Capsule (E) Capsules 100 mg 1 Capsule (E) Capsule (E) Capsule (E) Concentrate for 100 mg/ml 1 ml (E) Injection 1 ml (E) ml (E) : Cytotoxic medicines (i) Actinomycin D Injection 0.5 mg 1 Injection (E) Injection (E) (ii) Alpha Interferon Injection 3 million IU Each Pack (E) Each Pack (E) Each Pack (E)

36 (iii) Bleomycin Injection 15 mg 1 ml (E) ml (E) ml (E) (iv) Busulphan Tablets 2 mg 1 Tablet (E) Tablet (E) Tablet (E) (v) Cisplatin Injection 10 mg / vial Each Pack (E) Each Pack (E) Each Pack (E) Injection 50 mg / vial Each Pack (E) Each Pack (E) Each Pack (E) (vi) Cyclophosphamide Tablets 50 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 200 mg Injection 500 mg 1 Injectable (E) Injectable (E) Injectable (E) (vii) Cytosine arabinoside Injection 100 mg/vial Each Pack (E) Each Pack (E) Each Pack (E) Injection 500 mg/vial Each Pack (E) Each Pack (E) Each Pack (E) Injection 1000 mg/vial Each Pack (E) Each Pack (E) Each Pack (E) (viii) Danazol Capsules 50 mg 1 Capsule (E) Capsule (E) Capsule (E) Capsules 100 mg 1 Capsule (E) Capsule (E) Capsule (E) (ix) Doxorubicin Injection 10 mg Each Pack (E) Each Pack (E) Each Pack (E)

37 50 mg Each Pack (E) Each Pack (E) Each Pack (E) (x) Etoposide Capsules 100 mg 1 Capsule (E) Capsule (E) Capsule (E) Injection 100mg/5ml vial Each Pack (E) Each Pack (E) Each Pack (E) (xi) Flutamide Tablet 250 mg 1 Tablet (E) Tablet (E) Tablet (E) (xii) 5-Fluorouracil Injection 250 mg / 5 ml 1 ml (E) ml (E) ml (E) (xiii) Folinic Acid Injection 3 mg / ml (xiv) Gemcitabine hydrochloride Injection 200 mg Each Pack (E) Each Pack (E) Each Pack (E) Injection 1 gm Each Pack (E) Each Pack (E) Each Pack (E) (xv) L- Asparaginase Injection 5000 KU. Each Pack (E) Each Pack (E) Each Pack (E) (xvi) Melphalan Tablet 2 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablet 5 mg 1 Tablet (E) Tablet (E) Tablet (E) (xvii) Mercaptopurine Tablet 50 mg 1 Tablet (E) Tablet (E) Tablet (E) Injection 100 mg / ml

38 (xviii) Methotrexate Tablet 2.5 mg 1 Tablet (E) Tablet (E) Tablet (E) Injection 50 mg / ml 1 ml (E) ml (E) ml (E) (xix) Mitomycin-C Injection 10 mg Each Pack (E) Each Pack (E) Each Pack (E) (xx) Paclitaxel Injection 30 mg / 5 ml Each Pack (E) Each Pack (E) Each Pack (E) (xxi) Procarbazine Capsules 50 mg 1 Capsule (E) Capsule (E) Capsule (E) (xxii) Vinblastine Sulphate Injection 10 mg Each Pack (E) Each Pack (E) Each Pack (E) (xxiii) Vincristine Injection 1 mg / ml Each Pack (E) Each Pack (E) Each Pack (E) Added medicines (xxiv) Carboplatin Injection 150 mg vial Each Pack (E) Each Pack (E) Each Pack (E) Injection 450 mg vial Each Pack (E) Each Pack (E) Each Pack (E) (xv) Dacarbazine Injection 500 mg Each Pack (E) Each Pack (E) Each Pack (E) (xvi) Daunorubicin Injection 20 mg vial Each Pack (E) Each Pack (E) Each Pack (E) (xvii) Ifosfamide Injection 1 gm/2ml vial Each Pack (E) Corrigendum reg. S.O. No. 3558(E) dt (E) Each Pack (E) Each Pack (E)

39 (xviii) Mesna Injection 200 mg 1 ml (E) ml (E) ml (E) (xix) Oxaliplatin Injection 50 mg vial 1 Injectable (E) Injectable (E) Injectable (E) (xx) Imatinib Tablets 100 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 400 mg 1 Tablet (E) Tablet (E) Tablet (E) (xxi) Chlorambucil Tablets 2 mg 1 Tablet (E) Tablet (E) Tablet (E) : Hormones and antihormones (i) Prednisolone Tablets 5 mg 1 Tablet (E) Tablet (E) Tablet (E) Injection 20 mg (as 1 ml (E) sodium 1 ml (E) phosphate or succinate) Injection 25 mg (as sodium phosphate or succinate) (ii) Raloxifene Tablets 60 mg 1 Tablet (E) Tablet (E) Tablet (E) (iii) Tamoxifen Citrate Tablets 10 mg 1 Tablet (E) Tablet (E) Tablet (E) Tablets 20 mg 1 Tablet (E) Tablet (E) Tablet (E)

MEDICAL COLLEGE & HOSPITAL IN DOOR ESSENTIAL DRUG LIST

MEDICAL COLLEGE & HOSPITAL IN DOOR ESSENTIAL DRUG LIST ANNEXURE - D MEDICAL COLLEGE & HOSPITAL IN DOOR ESSENTIAL DRUG LIST Bihar EDL 1. Anaesthetics 1.1 Local Anaesthetics Bupivacaine Injection Plain-0.5% (5mg/ml) Hydrochloride Heavy-0.5% + 80mg/ml Dextrose

More information

for Extended Stability Parenteral Drugs Third Edition Caryn M. Bing, R.Ph., M.S., FASHP Editor

for Extended Stability Parenteral Drugs Third Edition Caryn M. Bing, R.Ph., M.S., FASHP Editor Extended Stability for Parenteral Drugs Third Edition Editor Caryn M. Bing, R.Ph., M.S., FASHP 1 American Society of Health-System Pharmacists Bethesda, Maryland Contents Preface Acknowledgments x/ Dedication

More information

NEW SCHEDULE H1 INSERTED IN DRUGS AND COSMETICS RULES :

NEW SCHEDULE H1 INSERTED IN DRUGS AND COSMETICS RULES : LOCOST 85, GIDC Estate, Por-Ramangamdi, N.H.8, Dist. Vadodara - 391 243 Gujarat, India. Tel. No.: (91-265) 2830009 Fax No.: (P.P.) 2831446 E-mail: locost@sify.com Website: www.locostindia.com A Public

More information

10mg/ml (sulfate or hydrochloride) in 1ml ampoule 10mg/5ml (sulfate or

10mg/ml (sulfate or hydrochloride) in 1ml ampoule 10mg/5ml (sulfate or Strategic Fund Medicine List / Lista de Medicamentos del Fondo Estratégico Version 5-30 August 2013 The therapeutic indications presented in this list of medicines appear as published in the 18th World

More information

WHO Model List of Essential Medicines for Children

WHO Model List of Essential Medicines for Children WHO Model List of Essential Medicines for Children 4th list (April 2013) (Final Amendments October 2013) Status of this document This is a reprint of the text on the WHO Medicines web site http://www.who.int/medicines/publications/essentialmedicines/en/index.html

More information

NATIONAL ESSENTIAL MEDICINES LIST OF PAKISTAN. Ministry of Health Government of Pakistan Islamabad

NATIONAL ESSENTIAL MEDICINES LIST OF PAKISTAN. Ministry of Health Government of Pakistan Islamabad NATIONAL ESSENTIAL MEDICINES LIST OF PAKISTAN Ministry of Health Government of Pakistan Islamabad 2007 CONTENTS PREFACE. i NATIONAL ESSENTIAL MEDICINES LIST FOURTH REVISION Explanatory Notes... ii 1: ANAESTHETICS...

More information

Dosing information in renal impairment

Dosing information in renal impairment No. Drug name Usual dose Adjustment for Renal failure estimated CrCl (ml/min) Aminoglycoside antibiotics 1 Amikacin 2 Gentamicin 7.5 mg /kg q 12 hr > 50-90 7.5 mg/kg q 12 hr 10-50 7.5 mg/kg q 24 hr < 10

More information

1 Manipulation of formulae and dilutions

1 Manipulation of formulae and dilutions 1 Manipulation of formulae and dilutions This first chapter of questions is specifically designed to cover a range of numeracy skills. It will give the user further experience in the skills of addition,

More information

Health (Drugs and Poisons) Regulation 1996. Drug Therapy Protocol Rural and Isolated Practice Area Endorsed Nurse

Health (Drugs and Poisons) Regulation 1996. Drug Therapy Protocol Rural and Isolated Practice Area Endorsed Nurse Health (Drugs and Poisons) Regulation 1996 Drug Therapy Protocol Rural and Isolated Practice Area Endorsed Nurse Health Protection Unit Medicines Regulation and Quality PO Box 21 Fortitude Valley BC QLD

More information

WHO Model List of Essential Medicines for Children

WHO Model List of Essential Medicines for Children WHO Model List of Essential Medicines for Children 2nd List (updated) March 2010 Status of this document This is a reprint of the text on the WHO Medicines web site http://www.who.int/medicines/publications/essentialmedicines/en/index.html

More information

Appendix 4: Guidelines for Prescribing and Administering Drugs:

Appendix 4: Guidelines for Prescribing and Administering Drugs: Appendix 4: Guidelines for Prescribing and Administering Drugs: A midwife may prescribe and administer the following substances in accordance with the guidelines approved by the Board. This list indicates

More information

WHO Model List of Essential Medicines

WHO Model List of Essential Medicines of Essential Medicines 17th list (March 2011) Status of this document This is a reprint of the text on the WHO Medicines web site http://www.who.int/medicines/publications/essentialmedicines/en/index.html

More information

No Essential Medicine Generic Name MAL Number Brand Name HS Code. Isoflurane Liquid MAL09020968A ISOFLURANE INHALATION LIQUID 100% V/V

No Essential Medicine Generic Name MAL Number Brand Name HS Code. Isoflurane Liquid MAL09020968A ISOFLURANE INHALATION LIQUID 100% V/V 1 1.1 ANAESTHETICS GENERAL ANAESTHETICS AND OXYGEN Isoflurane Isoflurane Liquid MAL19986452A AERRANE (INHALATION ANAESTHETIC) Isoflurane Liquid MAL19880325AC FORANE Isoflurane Liquid MAL09020968A ISOFLURANE

More information

Round 15-March 2016. Scope of the EoI: Anti-Retroviral (HIV/AIDs, Hepatitis B and C), anti-tuberculosis and anti- Malarial products

Round 15-March 2016. Scope of the EoI: Anti-Retroviral (HIV/AIDs, Hepatitis B and C), anti-tuberculosis and anti- Malarial products Global Fund, GDF and UNITAID Invitation to manufacturers of anti-retroviral, anti-tuberculosis and anti-malarial medicines to submit an Expression of Interest (EoI) for product evaluation by Expert Review

More information

Emergency Medical Items Catalogue 2002. Code Description Ind. price Ship. weight Ship. Vol.

Emergency Medical Items Catalogue 2002. Code Description Ind. price Ship. weight Ship. Vol. Injectable drugs DINJACSA5V ACETYLSALICYLAT LYSINE, 0.9 g (aspirin 0.5 g), powder vial Injectable analgesic, antipyretic, anti inflammatory. Not in the WHO Essential Medicines list 2002. Action is rapid,

More information

PREPARATIONS: Adrenaline 1mg in 1ml (1:1000) Adrenaline 100micrograms in 1ml (1:10,000)

PREPARATIONS: Adrenaline 1mg in 1ml (1:1000) Adrenaline 100micrograms in 1ml (1:10,000) ADRENALINE Acute hypotension Via a CENTRAL venous line Initially 100-300 nanograms/kg/minute 0.1-0.3 microgram/kg/minute adjusted according to response up to a maximum of 1.5 micrograms/kg/minute. Increase

More information

WHO Model List of Essential Medicines

WHO Model List of Essential Medicines of Essential Medicines 18th list (April 2013) (Final Amendments October 2013) Status of this document This is a reprint of the text on the WHO Medicines web site http://www.who.int/medicines/publications/essentialmedicines/en/index.html

More information

. ก ก 1. Actifed tab/syr. Triprolidine : should be stored in tight, light-resistant Pseudoepedrine : Triprolidine (p.25) Pseudoepedrine (p.

. ก ก 1. Actifed tab/syr. Triprolidine : should be stored in tight, light-resistant Pseudoepedrine : Triprolidine (p.25) Pseudoepedrine (p. ก ก. 2553 (p.807) 3. Adrenaline inj. 1mg/ml (Epinephrine inj.) ( Druginfor. p.629) 4. Aminophylline/ Theophylline inj. (Drug infor. Ed. 11 th p.1339) 5. Amlodipine + HCTZ (Moduretic). ก ก 1. Actifed tab/syr.

More information

Bioequivalence Study Design Considerations. Dr. John Gordon

Bioequivalence Study Design Considerations. Dr. John Gordon Bioequivalence Study Design Considerations Dr. John Gordon Key Output of Programme A list of prequalified medicinal products used for treatment of HIV/AIDS, malaria, tuberculosis, influenza, and for reproductive

More information

$10.00 PRESCRIPTION PROGRAM DETAILS

$10.00 PRESCRIPTION PROGRAM DETAILS $10.00 PRESCRIPTION PROGRAM DETAILS 1. The $10.00 program applies only to certain generic drugs at commonly prescribed 90 day usage dosages. (See list). 2. The Program may change without notification and

More information

AS AMENDED IN THE SENATE. Legal Supplement Part C to the Trinidad and Tobago Gazette, Vol. 41, No. 218, 18th November, 2002. No.

AS AMENDED IN THE SENATE. Legal Supplement Part C to the Trinidad and Tobago Gazette, Vol. 41, No. 218, 18th November, 2002. No. AS AMENDED IN THE SENATE Legal Supplement Part C to the Trinidad and Tobago Gazette, Vol. 41, No. 218, 18th November, 2002 No. 1 of 2014 Fourth Session Tenth Parliament Republic of Trinidad and Tobago

More information

DRUG CALCULATIONS. Mathematical accuracy is a matter of life and death. [Keighley 1984]

DRUG CALCULATIONS. Mathematical accuracy is a matter of life and death. [Keighley 1984] DRUG CALCULATIONS Mathematical accuracy is a matter of life and death. [Keighley 1984] At the end of this practice sheet, you will be able to: Perform simple arithmetical tasks. Accurately calculate drug

More information

MINISTRY OF HEALTH. Republic of Uganda. Essential Medicines and Health Supplies List for Uganda (EMHSLU)

MINISTRY OF HEALTH. Republic of Uganda. Essential Medicines and Health Supplies List for Uganda (EMHSLU) MINISTRY OF HEALTH Republic of Uganda Essential Medicines and Health Supplies List for Uganda (EMHSLU) 2012 Essential Medicines and Health Supplies List for Uganda 2012 (EMHSLU) All parts of this publication

More information

Medications most likely to be seen in primary care

Medications most likely to be seen in primary care Hazardous Medicines The majority of medicines are not classed as hazardous. The only medicinal products that are automatically deemed to be hazardous are cytotoxic and cytostatic medicines. There is no

More information

DRUGS BY THERAPEUTIC GROUP

DRUGS BY THERAPEUTIC GROUP DRUGS BY THERAPEUTIC GROUP You will find hereafter the medicines used by MSF sorted according to the WHO Therapeutic Groups classification Section 1: Anaesthetics 1.1. General anaesthetics and oxygen HALOTHANE,

More information

WHO Model List of Essential Medicines

WHO Model List of Essential Medicines of Essential Medicines 18th list (April 2013) Status of this document This is a reprint of the text on the WHO Medicines web site http://www.who.int/medicines/publications/essentialmedicines/en/index.html

More information

PROJECT LIST GENERIC PRODUCTS

PROJECT LIST GENERIC PRODUCTS PROJECT LIST GENERIC PRODUCTS Acetylcysteine, Effervescent tablets 200 mg, 600 mg Alendronate sodium, Tablets 10, 70 mg Alfuzosin,Tablets 2.5mg Alfuzosin, ER Tablets 10 mg Ambroxol, Effervescent tablets

More information

Hydration, IV Infusions, Injections and Vaccine Charge Process

Hydration, IV Infusions, Injections and Vaccine Charge Process There are a number of items to be considered when billing for the Nursing service to perform drug therapy, the charge process is divided into three specific groups of codes and processes. 1. Hydration

More information

Dosage Calculations INTRODUCTION. L earning Objectives CHAPTER

Dosage Calculations INTRODUCTION. L earning Objectives CHAPTER CHAPTER 5 Dosage Calculations L earning Objectives After completing this chapter, you should be able to: Solve one-step pharmaceutical dosage calculations. Set up a series of ratios and proportions to

More information

Analysis of price components of essential medicines in India: policy options for improving access to medicines

Analysis of price components of essential medicines in India: policy options for improving access to medicines Analysis of price components of essential medicines in India: policy options for improving access to medicines Anita Kotwani Department of Pharmacology, V.P.Chest Institute, University of Delhi, Delhi,

More information

Drugs & Everything Else

Drugs & Everything Else Pain Relief, Common Drugs & Everything Else Henrik Jörnvall MD, PhD MKAIC November 11 2011 Lidocaine Noradrenaline Isoflurane Morphine Ropivacaine Platelets l t Pethidine Dobutamine Propofol Normal Saline

More information

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet 02300699 1 tablet daily. Complera 200/25/300 mg tablet 02374129 1 tablet daily

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet 02300699 1 tablet daily. Complera 200/25/300 mg tablet 02374129 1 tablet daily HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ emtricitabine/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ emtricitabine/

More information

FORMULARY. (List of Covered Drugs) Molina Dual Options Medicare-Medicaid Plan

FORMULARY. (List of Covered Drugs) Molina Dual Options Medicare-Medicaid Plan FORMULARY (List of Covered Drugs) 2015 Molina Dual Options Medicare-Medicaid Plan Version 14 UPDATED: 11/2015 Member Services (877) 901-8181, TTY/TDD 711 Monday - Friday, 8 a.m. - 8 p.m. local time H8046_15_16003_0002_MMPILRx

More information

Anti Protozoal. Albendazole Oral Suspension USP Albendazole Tablets USP 400 mg Anti Malarial

Anti Protozoal. Albendazole Oral Suspension USP Albendazole Tablets USP 400 mg Anti Malarial ANTI-INFECTIVES Anti Biotics Levofloxacin Tablets 250, 500, 750 mg Ofloxacin Tablets 200, 400 mg Sparfloxacin Tablets 200 mg Ciprofloxacin Tablets USP 250, 500 mg Ofloxacin & Ornidazole Tablets Nitrofurantoin

More information

Order No. Date Surgery DRUG ORDER SHEET. Page 1. Quantity Unit Total Ordered Cost Cost. Order No. Date

Order No. Date Surgery DRUG ORDER SHEET. Page 1. Quantity Unit Total Ordered Cost Cost. Order No. Date Order No. Surgery Page 1 Aciclovir 800mg (35) Tabs Aciclovir 400mg (56) Tabs Adrenaline 1:10000 Aerospacer adult Aerospacer child/baby with mask Amitriptiline 10mg Amoxicillin 125/5 syrup 100 mls Amoxicillin

More information

EL PASO COUNTY DEPARTMENT OF HUMAN RESOURCES. Family and Medical Leave

EL PASO COUNTY DEPARTMENT OF HUMAN RESOURCES. Family and Medical Leave EL PASO COUNTY DEPARTMENT OF HUMAN RESOURCES Family and Medical Leave Revised Date: El Paso County shall provide eligible employees up to 12 weeks of unpaid leave per year for certain family and medical

More information

PROFESSIONAL BOARD FOR EMERGENCY CARE

PROFESSIONAL BOARD FOR EMERGENCY CARE PROFESSIONAL BOARD FOR EMERGENCY CARE IMPORTANT NOTICE TO ALL EMERGENCY CARE PRACTITIONERS INTRODUCTION OF NEW SCOPE OF PRACTICE FOR REGISTERED EMERGENCY CARE PRACTITIONERS NOVEMBER 2009 Herewith the July

More information

SOURCES AND PRICES OF SELECTED MEDICINES FOR CHILDREN

SOURCES AND PRICES OF SELECTED MEDICINES FOR CHILDREN SOURCES AND PRICES OF SELECTED MEDICINES FOR CHILDREN INCLUDING THERAPEUTIC FOOD, DIETARY VITAMIN AND MINERAL SUPPLEMENTATION 2 nd EDITION APRIL 2010 TABLE OF CONTENTS LIST OF ABBREVIATIONS 4 ABOUT THIS

More information

$4, 30-day $10, 90-day

$4, 30-day $10, 90-day $4 Prescriptions - Choose from hundreds of generic drugs and over the counter medications. Free Home Delivery Mailed right to your home Free shipping Prescription Program includes up to a 30-day supply

More information

Complete Pharmacy Technician Certificate Program 230 clock hours

Complete Pharmacy Technician Certificate Program 230 clock hours Complete Pharmacy Technician Certificate Program 230 clock hours Course Description Our Pharmacy Technician Career Training Program will give the pharmacy technician the knowledge to achieve the competencies

More information

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

More information

Attachment I Coverage of the Healthcare Products Sector

Attachment I Coverage of the Healthcare Products Sector 1 1211.10.10 - - Cut, crushed or powdered form 2 1211.10.90 - - Other 3 1211.20.10 - - Cut, crushed or powdered form 4 1211.20.90 - - Other 5 1211.30.10 - - Cut, crushed or powdered form 6 1211.30.90 -

More information

The Transfer of Funds (Alderney) Ordinance, 2007

The Transfer of Funds (Alderney) Ordinance, 2007 The Transfer of Funds (Alderney) Ordinance, 2007 ARRANGEMENT OF SECTIONS PART I INFORMATION TO ACCOMPANY TRANSFERS OF FUNDS 1. Application. 2. Information accompanying transfers of funds and record keeping.

More information

SOURCES AND PRICES OF SELECTED MEDICINES FOR CHILDREN

SOURCES AND PRICES OF SELECTED MEDICINES FOR CHILDREN SOURCES AND PRICES OF SELECTED MEDICINES FOR CHILDREN INCLUDING THERAPEUTIC FOOD, DIETARY VITAMIN AND MINERAL SUPPLEMENTATION JANUARY 2009 UNICEF in collaboration with WHO CONTENTS 1. EXECUTIVE SUMMARY...

More information

Orbit Group Advisory Services LLC INVESTMENT ADVISORY CONTRACT. 100 International Drive, Buffalo, New York 14221

Orbit Group Advisory Services LLC INVESTMENT ADVISORY CONTRACT. 100 International Drive, Buffalo, New York 14221 Orbit Group Advisory Services LLC INVESTMENT ADVISORY CONTRACT 100 International Drive, Buffalo, New York 14221 Version Date: 03/12/2015 The undersigned ( Client ), being duly authorized, has established

More information

Autism Spectrum Disorder Formulation & Resource Guide

Autism Spectrum Disorder Formulation & Resource Guide Autism Spectrum Disorder Formulation & Resource Guide Autism Spectrum Disorder Formulation & Resource Guide Knowledge Changes Everything: Quality. Innovation. Experience. Since 1974. 2015 College Pharmacy

More information

Berkshire Healthcare NHS Foundation Trust Becky White CHS Pharmacist April 2013

Berkshire Healthcare NHS Foundation Trust Becky White CHS Pharmacist April 2013 Berkshire Healthcare NHS Foundation Trust Becky White CHS Pharmacist April 2013 Access to palliative care drugs out of hours Agreement set up with local community pharmacy s to hold stock of commonly prescribed

More information

Explanatory notes. Annex 1 19th WHO Model List of Essential Medicines (April 2015)

Explanatory notes. Annex 1 19th WHO Model List of Essential Medicines (April 2015) Annex 1 19th of Essential Medicines (April 2015) Explanatory notes The core list presents a list of minimum medicine needs for a basic health care system, listing the most efficacious, safe and cost effective

More information

Privacy Statement Relating to the Collection, Use and Disclosure of Personal Data & Customer Information

Privacy Statement Relating to the Collection, Use and Disclosure of Personal Data & Customer Information Privacy Statement Relating to the Collection, Use and Disclosure of Personal Data & Customer Information Safeguarding personal data and customer information and using it in a lawful manner, consistent

More information

Date: November 30, 2010

Date: November 30, 2010 Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Date: November 30, 2010 To: Through: From: Subject: Drug Name(s): Application

More information

Pain Relief & Common Drugs. Henrik Jörnvall MD, PhD

Pain Relief & Common Drugs. Henrik Jörnvall MD, PhD Pain Relief & Common Drugs Henrik Jörnvall MD, PhD MKAIC May 5 2010 Pain Definition An unpleasant sensory and emotional experience assocated with actual or potential tissue damage or described in terms

More information

INTER-AMERICAN CONVENTION TO FACILITATE DISASTER ASSISTANCE. Preamble

INTER-AMERICAN CONVENTION TO FACILITATE DISASTER ASSISTANCE. Preamble INTER-AMERICAN CONVENTION TO FACILITATE DISASTER ASSISTANCE Preamble CONSIDERING the frequency of disasters, catastrophes, and calamities that take and threaten the lives, safety, and property of the inhabitants

More information

Retail Prescription Program Drug List

Retail Prescription Program Drug List Retail Prescription Program Drug List Price Matters New Men s Health Category Convenience Free Home Delivery Our 4 prescriptions have saved our customers over 3 billion The program is available to everyone,

More information

Home Delivery Prescription Program Drug List

Home Delivery Prescription Program Drug List Home Delivery Prescription Program Drug List Low-cost prescriptions, right in your mailbox. Now you can have your generic prescriptions mailed right to your home, no matter where you live. Because we think

More information

The Transfer of Funds (Sark) Ordinance, 2007 a

The Transfer of Funds (Sark) Ordinance, 2007 a The Transfer of Funds (Sark) Ordinance, 2007 a [CONSOLIDATED TEXT] NOTE This consolidated version of the enactment incorporates all amendments listed in the footnote below. However, while it is believed

More information

Workflow Administration of Windchill 10.2

Workflow Administration of Windchill 10.2 Workflow Administration of Windchill 10.2 Overview Course Code Course Length TRN-4339-T 2 Days In this course, you will learn about Windchill workflow features and how to design, configure, and test workflow

More information

BC Cancer Agency & Canadian Cancer Society Financial Support Drug Program (FSDP) for Cancer Patients. Drug Benefit List. Updated February 15, 2016

BC Cancer Agency & Canadian Cancer Society Financial Support Drug Program (FSDP) for Cancer Patients. Drug Benefit List. Updated February 15, 2016 BC Cancer Agency & Canadian Cancer Society Financial Support Drug Program (FSDP) for Cancer Patients Drug Benefit List Updated February 15, 2016 The FSDP will operate following rules established by the

More information

PART A: OVERVIEW...1 1. INTRODUCTION...1 2. APPLICABILITY...1 3. OBJECTIVE...1 PART B: LEGAL PROVISIONS...2 4. LEGAL PROVISIONS...

PART A: OVERVIEW...1 1. INTRODUCTION...1 2. APPLICABILITY...1 3. OBJECTIVE...1 PART B: LEGAL PROVISIONS...2 4. LEGAL PROVISIONS... PART A: OVERVIEW...1 1. INTRODUCTION...1 2. APPLICABILITY...1 3. OBJECTIVE...1 PART B: LEGAL PROVISIONS...2 4. LEGAL PROVISIONS...2 PART C: POLICY...2 5. SCOPE OF ACTIVITIES THAT CAN BE OUTSOURCED...2

More information

PROPOSAL TO WAIVE IN VIVO BIOEQUIVALENCE REQUIREMENTS FOR THE WHO MODEL LIST OF ESSENTIAL MEDICINES IMMEDIATE RELEASE, SOLID ORAL DOSAGE FORMS

PROPOSAL TO WAIVE IN VIVO BIOEQUIVALENCE REQUIREMENTS FOR THE WHO MODEL LIST OF ESSENTIAL MEDICINES IMMEDIATE RELEASE, SOLID ORAL DOSAGE FORMS WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTE Working document QAS/04.109/Rev.1 page 1 PROPOSAL TO WAIVE IN VIVO BIOEQUIVALENCE REQUIREMENTS FOR THE WHO MODEL LIST OF ESSENTIAL MEDICINES

More information

The levy of VAT is administered by the Goa Value Added Tax Act, 2005 and the rules made thereunder.

The levy of VAT is administered by the Goa Value Added Tax Act, 2005 and the rules made thereunder. Frequently Asked Questions 1. What is VAT? VAT is the short form of Value Added Tax. VAT is the tax that has replaced the earlier levy of Sales Tax. Under the earlier first point system of levy of tax,

More information

Regulation On Attainment of Doctor of Sciences Degree at SEEU (PhD)

Regulation On Attainment of Doctor of Sciences Degree at SEEU (PhD) According to article 118 of the Law on Higher Education of Republic of Macedonia; articles 60, 68 and 69 of SEEU statute ; based on decision of Council of Teaching and Science of SEEU of date April 12th

More information

THE DRUGS AND COSMETICS RULES, 1945

THE DRUGS AND COSMETICS RULES, 1945 THE DRUGS AND COSMETICS RULES, 1945 PART VI SALE OF DRUGS OTHER THAN HOMOEOPATHIC MEDICINES 59. (1) The State Government shall appoint Licensing Authorities for the purpose of this Part for such areas

More information

LDU Maths, Stats and Numeracy Support. Metric Conversions

LDU Maths, Stats and Numeracy Support. Metric Conversions Metric Conversions Here are some metric weights arranged in size order, starting with the biggest:- Kg (kilogram) g (gram) mg (milligram) mcg (microgram) Each one is a thousand (1000) times smaller than

More information

Frank Zanzuccki, Executive Director. See Summary below for explanation of exception to calendar requirement

Frank Zanzuccki, Executive Director. See Summary below for explanation of exception to calendar requirement LAW AND PUBLIC SAFETY NEW JERSEY RACING COMMISSION Horse Racing Medication and Testing Procedures Proposed Amendment: Authorized By: N.J.A.C. 13:70-14A.9 New Jersey Racing Commission, Frank Zanzuccki,

More information

Palliative Care Drug Plan (Plan P) Formulary List of drugs PharmaCare covers

Palliative Care Drug Plan (Plan P) Formulary List of drugs PharmaCare covers Palliative Care Drug Plan (Plan P) Formulary List of drugs PharmaCare covers Important Notes: Last Updated: May 11, 2015 Pharmacists must submit a claim on PharmaNet at the time of purchase to enable coverage.

More information

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div. Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under

More information

Guide to The Notification System for Exempt Medicinal Products

Guide to The Notification System for Exempt Medicinal Products Guide to The Notification System for Exempt Medicinal Products AUT-G0090-1 10 JULY 2014 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.

More information

DRUG DRIVING OFFENCES

DRUG DRIVING OFFENCES DRUG DRIVING OFFENCES Taking drug can affect body and mind coordination that can significantly impair the ability to drive a motor vehicle. Road Traffic Ordinance (Cap 374) was amended in 2011 in order

More information

16.19.10.11 PUBLIC HEALTH CLINICS: A. CLINIC LICENSURE: (1) All clinics where dangerous drugs are administered, distributed or dispensed shall obtain

16.19.10.11 PUBLIC HEALTH CLINICS: A. CLINIC LICENSURE: (1) All clinics where dangerous drugs are administered, distributed or dispensed shall obtain 16.19.10.11 PUBLIC HEALTH CLINICS: A. CLINIC LICENSURE: (1) All clinics where dangerous drugs are administered, distributed or dispensed shall obtain a limited drug permit as described in Section 61-11-14

More information

IN THE COUNCIL OF THE DISTRICT OF COLUMBIA

IN THE COUNCIL OF THE DISTRICT OF COLUMBIA Codification District of Columbia Official Code IN THE COUNCIL OF THE DISTRICT OF COLUMBIA 2001 Edition 2004 Fall Supp. West Group Publisher To provide greater access and participation in public services,

More information

Emergency Medications Approved for Use at VAPAHCS

Emergency Medications Approved for Use at VAPAHCS Table 1: Medications (PAD GM&S) Emergency Medications Approved for Use at VAPAHCS PAD GM&S (See HCSM 11-12-35 Attachment A CPR Committee Atropine 1mg/10ml syringe X 3 Normal saline 1000ml bag X 2 Sodium

More information

NOTICES. Approved and Required Medications Lists for Emergency Medical Services Agencies and Emergency Medical Services Providers

NOTICES. Approved and Required Medications Lists for Emergency Medical Services Agencies and Emergency Medical Services Providers NOTICES Approved and Required Medications Lists for Emergency Medical Services Agencies and Emergency Medical Services Providers [45 Pa.B. 5451] [Saturday, August 29, 2015] Under 28 Pa. Code 1027.3(c)

More information

PROPOSALS FOR AMENDMENTS TO THE HUMAN MEDICINES REGULATIONS 2012 TO ALLOW WIDER ACCESS TO NALOXONE FOR USE IN EMERGENCIES

PROPOSALS FOR AMENDMENTS TO THE HUMAN MEDICINES REGULATIONS 2012 TO ALLOW WIDER ACCESS TO NALOXONE FOR USE IN EMERGENCIES To: Interested Organisations Our reference: MLX MLX 383 Date: 19 November 2013 Dear Sir/Madam PROPOSALS FOR AMENDMENTS TO THE HUMAN MEDICINES REGULATIONS 2012 TO ALLOW WIDER ACCESS TO NALOXONE FOR USE

More information

Cosmetic products safety regulations

Cosmetic products safety regulations Cosmetic products safety regulations Trading Standards Information www.southwark.gov.uk 1. Introduction Cosmetic products are subject to EU wide safety regulations. They must not be liable to cause damage

More information

16 HB 362/AP A BILL TO BE ENTITLED AN ACT

16 HB 362/AP A BILL TO BE ENTITLED AN ACT House Bill 362 (AS PASSED HOUSE AND SENATE) By: Representatives Clark of the 101 st, Cooper of the 43 rd, Fleming of the 121 st, Coleman of the 97 th, Carter of the 175 th, and others A BILL TO BE ENTITLED

More information

After section 80B of the Income-tax Act, the following section shall be inserted with effect from the 1st day of April, 2006, namely:

After section 80B of the Income-tax Act, the following section shall be inserted with effect from the 1st day of April, 2006, namely: Insertion of new section 80C. After section 80B of the Income-tax Act, the following section shall be inserted with effect from the 1st day of April, 2006, namely: 80C. Deduction in respect of life insurance

More information

GENERAL TERMS ANC CONDITIONS OF BROKERAGE SERVICES PROVIDED BY BZ WBK BROKERAGE S.A. (UNIFORM TEXT)

GENERAL TERMS ANC CONDITIONS OF BROKERAGE SERVICES PROVIDED BY BZ WBK BROKERAGE S.A. (UNIFORM TEXT) Appendix to the Resolution No. 17/2011 of the Management Board of BZ WBK Brokerage S.A. dated 25 February 2011 concerning adoption of the amended General Terms and Conditions of Brokerage Services Provided

More information

AETNA BETTER HEALTH OF OHIO a MyCare Ohio plan

AETNA BETTER HEALTH OF OHIO a MyCare Ohio plan AETNA BETTER HEALTH OF OHIO a MyCare Ohio plan 2015 List of Covered Drugs/Formulary Aetna Better Health of Ohio, a MyCare Ohio plan (Medicare-Medicaid Plan) is a health plan that contracts with Medicare

More information

School Nutrition Programs VENDOR CONTRACT Between

School Nutrition Programs VENDOR CONTRACT Between Form #233 Rev. 3/15 LOCAL EDUCATION AGENCY/COMMERCIAL VENDOR CONTRACT TEMPLATE School Nutrition Programs VENDOR CONTRACT Between Local Education Agency: Agreement Number: Address: Contact Person: Phone:

More information

INTERNAL REGULATIONS OF THE AUDIT AND COMPLIANCE COMMITEE OF BBVA COLOMBIA

INTERNAL REGULATIONS OF THE AUDIT AND COMPLIANCE COMMITEE OF BBVA COLOMBIA ANNEX 3 INTERNAL REGULATIONS OF THE AUDIT AND COMPLIANCE COMMITEE OF BBVA COLOMBIA (Hereafter referred to as the Committee) 1 INDEX CHAPTER I RULES OF PROCEDURE OF THE BOARD OF DIRECTORS 1 NATURE 3 2.

More information

Final Terms dated 2 December, 2015. ROYAL BANK OF CANADA (a Canadian chartered bank)

Final Terms dated 2 December, 2015. ROYAL BANK OF CANADA (a Canadian chartered bank) Final Terms dated 2 December, 2015 ROYAL BANK OF CANADA (a Canadian chartered bank) Issue of SEK TBC Booster Notes Linked to OMXS30 Index due December 2021 under the Programme for the Issuance of Securities

More information

website: www.nfdcindia.com E-mail: nfdc@nfdcindia.com BYE-LAWS & REGULATIONS

website: www.nfdcindia.com E-mail: nfdc@nfdcindia.com BYE-LAWS & REGULATIONS NATIONAL FILM DEVELOPMENT CORPORATION LIMITED (A Government of India Enterprise) Discovery of India Bldg. Nehru Centre, Dr. A. B. Road, Worli, Mumbai 400018. website: www.nfdcindia.com E-mail: nfdc@nfdcindia.com

More information

Maths for Healthcare Professionals

Maths for Healthcare Professionals Maths for Healthcare Professionals Mathematics Skills Guide All the information that you require to enable you to pass the mathematics tests within your course is contained within. Contents Fractions Page

More information

GDUFA Regulatory Science Update

GDUFA Regulatory Science Update GDUFA Regulatory Science Update Robert Lionberger, Ph.D. Director Office of Research and Standards Office of Generic Drugs Center for Drug Evaluation and Research, FDA GPhA Annual Meeting Feb 9, 2015 Goals

More information

Pro-iii Insurance Innovators Inc. Po Box 969, 130 S. Easton Rd. Glenside, PA 19038 P-215-885-7300 F-215-886-2482 Email: Sam@iiigroup.

Pro-iii Insurance Innovators Inc. Po Box 969, 130 S. Easton Rd. Glenside, PA 19038 P-215-885-7300 F-215-886-2482 Email: Sam@iiigroup. ADMIRAL INSURANCE COMPANY 1255 Caldwell Road Cherry Hill, NJ 08034 Phone: 856-429-9200 Fax: 856-429-8611 Internet: http://www.admiralins.com Pro-iii Insurance Innovators Inc. Po Box 969, 130 S. Easton

More information

Patent Cooperation Treaty (PCT)

Patent Cooperation Treaty (PCT) (PCT) Done at Washington on June 19, 1970, amended on September 28, 1979, modified on February 3, 1984, and on October 3, 2001 Editor s Note: For details concerning amendments and modifications to the

More information

CICLOSPORIN. What are the aims of this leaflet?

CICLOSPORIN. What are the aims of this leaflet? CICLOSPORIN What are the aims of this leaflet? This leaflet has been written to help you understand more about ciclosporin. It tells you what it is, how it works, how it is used to treat skin conditions,

More information

WOMEN OWNED SMALL BUSINESS (WOSB) PROGRAM CERTIFICATION ECONOMICALLY DISADVANATGED or EDWOSB

WOMEN OWNED SMALL BUSINESS (WOSB) PROGRAM CERTIFICATION ECONOMICALLY DISADVANATGED or EDWOSB WOMEN OWNED SMALL BUSINESS (WOSB) PROGRAM CERTIFICATION ECONOMICALLY DISADVANATGED or EDWOSB All EDWOSBs that are interested in submitting an offer on a solicitation that has been set aside for WOSBs under

More information

Fresenius Kabi Creating a Global Leader in I.V. Generic Drugs. Conference Call, July 7, 2008

Fresenius Kabi Creating a Global Leader in I.V. Generic Drugs. Conference Call, July 7, 2008 Fresenius Kabi Creating a Global Leader in I.V. Generic Drugs Conference Call, July 7, 2008 Disclaimer THIS PRESENTATION IS FOR INFORMATION PURPOSES ONLY AND MAY NOT BE FURTHER DISTRIBUTED OR PASSED ON

More information

1 Medicines for Human Use: POM, P, GSL & General Pharmacy Regulations

1 Medicines for Human Use: POM, P, GSL & General Pharmacy Regulations General Legal Requirements A guide for pharmacists in Northern Ireland 2010 Edition 1 Medicines for Human Use: POM, P, GSL & General Pharmacy Regulations 1 MEDICINES FOR HUMAN USE Classes of medicinal

More information

PHARMACEUTICAL EXCIPIENTS

PHARMACEUTICAL EXCIPIENTS PHARMACEUTICAL EXCIPIENTS Brian R Matthews PDA Bethesda, MD, USA DHI Publishing, LLC River Grove, IL, USA 10 9 8 7 6 5 4 3 2 1 ISBN: x-xxxxxx-xx-x Copyright 2005 Brian R Matthews. All rights reserved.

More information

How To Make Index Option Contracts In Karnival Stock Exchange

How To Make Index Option Contracts In Karnival Stock Exchange REGULATIONS GOVERNING INDEX OPTION CONTRACTS [Gazette Notification of MAY 02, 2012] REGULATIONS GOVERNING INDEX OPTION CONTRACTS OF THE KARACHI STOCK EXCHANGE (GUARANTEE) LIMITED 1. PREAMBLE WHEREAS in

More information

Drug Use Review. Edward Cox, M.D. Director Office of Antimicrobial Products

Drug Use Review. Edward Cox, M.D. Director Office of Antimicrobial Products Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Drug Use Review Date: April 5, 2012 To: Through: Edward Cox, M.D. Director

More information

AGENCY MANAGEMENT FRAMEWORK FOR INSURANCE AGENT

AGENCY MANAGEMENT FRAMEWORK FOR INSURANCE AGENT GENERAL INSURANCE ASSOCIATION OF SINGAPORE AGENCY MANAGEMENT FRAMEWORK FOR INSURANCE AGENT APPENDIX B1 OF GIARR General Insurance Association of Singapore 180 Cecil Street, #15-01 Bangkok Bank Building

More information

PURCHASING POLICY & PROCEDURES. Table of Contents

PURCHASING POLICY & PROCEDURES. Table of Contents Table of Contents I. Purpose...3 II.Objective... 3 III.Scope... 3 IV.Policy Statement....3 V.When Does The Purchasing Staff Need To Be Involved... 3 VI.Who is Authorized to Legally Commit Morehouse School

More information

PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013)

PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) January 2013 RESTRICTED PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) DRAFT FOR COMMENTS Please address any comments on this proposal

More information

Service Specification for NHS Community Pharmacy Palliative Care Drugs Stockist Scheme

Service Specification for NHS Community Pharmacy Palliative Care Drugs Stockist Scheme Service Specification for NHS Community Pharmacy Palliative Care Drugs Stockist Scheme 1. This agreement is between NHS England North Midlands (Derbyshire/ Nottinghamshire only) (the Commissioner) Birch

More information

XL REINSURANCE SEGMENT PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 2001

XL REINSURANCE SEGMENT PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 2001 XL REINSURANCE SEGMENT PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 2001 (Expressed in thousands of US Dollars) Technical account: non-life 2001 Gross premiums

More information

Packaging Guidelines Version Date: 11/6/12. ABB Inc. Packaging Guidelines. Version 1.0. Page 1. 3.04.P08.W03 Rev 0

Packaging Guidelines Version Date: 11/6/12. ABB Inc. Packaging Guidelines. Version 1.0. Page 1. 3.04.P08.W03 Rev 0 ABB Inc. Packaging Guidelines Version 1.0 Page 1 Contents Master Carton:... 3 Data Requirements... 3 Barcodes... 5 Label Placement... 6 Packing List... 7 Page 1 Contents... 7 Page 2 Contents... 9 International

More information

on the transfer of personal data from the European Union

on the transfer of personal data from the European Union on the transfer of personal data from the European Union BCRsseptembre 2008.doc 1 TABLE OF CONTENTS I. PRELIMINARY REMARKS 3 II. DEFINITIONS 3 III. DELEGATED DATA PROTECTION MANAGER 4 IV. MICHELIN GROUP

More information